Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Agios Pharmaceuticals (AGIO) Gross Margin (2017 - 2025)

Agios Pharmaceuticals' Gross Margin history spans 8 years, with the latest figure at 90.59% for Q4 2025.

  • For Q4 2025, Gross Margin rose 233.0% year-over-year to 90.59%; the TTM value through Dec 2025 reached 88.26%, down 33.0%, while the annual FY2025 figure was 88.26%, 33.0% down from the prior year.
  • Gross Margin reached 90.59% in Q4 2025 per AGIO's latest filing, up from 86.96% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 92.34% in Q1 2024 to a low of 59.25% in Q1 2022.
  • Average Gross Margin over 4 years is 86.87%, with a median of 89.19% recorded in 2023.
  • The largest YoY upside for Gross Margin was 3087bps in 2023 against a maximum downside of -871bps in 2023.
  • A 4-year view of Gross Margin shows it stood at 90.42% in 2022, then rose by 1bps to 91.75% in 2023, then decreased by -4bps to 88.26% in 2024, then rose by 3bps to 90.59% in 2025.
  • Per Business Quant, the three most recent readings for AGIO's Gross Margin are 90.59% (Q4 2025), 86.96% (Q3 2025), and 86.33% (Q2 2025).